• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeu ADR (NQ: SMMT )

    10.09 +0.13 (+1.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,445,427
    Open 9.870
    Bid (Size) 10.05 (19)
    Ask (Size) 10.09 (69)
    Prev. Close 9.960
    Today's Range 9.650 - 10.20
    52wk Range 1.520 - 11.25
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
    What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
    Via Investor's Business Daily
    Topics Government
    Exposures Political
    IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
    Via Benzinga

    Performance

    YTD
    +282.20%
    +282.20%
    1 Month
    +26.12%
    +26.12%
    3 Month
    +189.11%
    +189.11%
    6 Month
    +167.64%
    +167.64%
    1 Year
    +407.04%
    +407.04%

    More News

    Read More
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    7 Top Stocks Under $10: June 2024 Edition
    Via InvestorPlace
    3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
    Via The Motley Fool
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Via Talk Markets
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Why Summit Therapeutics Stock Is Trading 8% Higher Monday
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Day Trading During A Slow Holiday Week
    Via Talk Markets
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Via Talk Markets
    Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
    From Summit Therapeutics Inc.
    Via Business Wire
    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
    From Summit Therapeutics Inc.
    Via Business Wire
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
    From Summit Therapeutics Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.